ALGOTHERAPEUTIX
15.12.2020 08:17:14 CET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Given a positive outcome of the approved Phase 1 study, the company intends to initiate Phase 2 by the end of 2021.
Stéphane Thiroloix , Founder & CEO of AlgoTherapeutix, says: “I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002 )
About AlgoTherapeutix
AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. More information at www.algotx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Laserfiche Announces 2026 Run Smarter® Award Winners18.3.2026 15:17:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — today announced the winners of the 2026 Laserfiche Run Smarter® Awards. These awards celebrate the visionaries and trailblazers who are redefining the possible, using Laserfiche to break down operational silos and catalyze a new era of enterprise-wide productivity. From a large city reimagining criminal justice to a financial services firm’s innovative use of AI for smarter service delivery: The winners enhance productivity, reimagine processes and improve lives with Laserfiche technology. “The true power of Laserfiche has always been in how it unlocks value — whether that is through delivering actionable intelligence, cost savings, or reclaimed time to put toward innovation,” said Karl Chan, CEO of Laserfiche. “This year’s honorees are at the forefront of information management, with many of them leveraging cloud and AI technology to modernize processes and achieve business transformation.” Congratulations to t
I-Pulse Acquires CSI Technologies to Strengthen U.S. High-Energy Capacitor Manufacturing Capabilities18.3.2026 14:30:00 CET | Press release
I-Pulse Acquires California Capacitor Specialist CSI Technologies to Advance Disruptive Pulsed Power ApplicationsCSI Acquisition Secures Strategic Technologies Central to I-Pulse’s Pulsed Power Roadmap Co-Founder, Chairman, and CEO, Robert Friedland, and Co-Founder and Chief Technology Officer, Laurent Frescaline, of I-Pulse, the world leader in high pulsed power technologies, are pleased to announce the acquisition of CSI Technologies, Inc., the California-based manufacturer of high-energy, high-voltage capacitors serving industrial, medical, and defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318099794/en/ The strategic acquisition enhances I-Pulse’s pulsed power development and U.S. manufacturing capabilities, particularly in mining, geothermal energy, mineral exploration, and water resource applications. By integrating CSI Technologies’ proven capacitor design and production expertise, I-Pulse str
Elliptic Integrates With Tempo, the Payments-First Blockchain18.3.2026 14:15:00 CET | Press release
Elliptic, the leader in digital asset decisioning, today announced full blockchain coverage for Tempo, the payments-first Layer-1 blockchain incubated by Stripe and Paradigm. With this integration, compliance and investigation teams gain full visibility into one of the most significant expansions of real-world financial activity onto blockchain infrastructure. "We're excited to have Elliptic providing compliance infrastructure on Tempo from day one. As payments move onchain at scale, builders and their customers need real-time tools to meet regulatory requirements without slowing down." – Nischay Upadhyayula, GTM, Tempo Tempo is a Layer-1 blockchain designed for real-world payments at scale, with sub-second finality and high throughput. Incubated by Stripe and Paradigm, Tempo is built for the transaction volumes that global commerce demands. Elliptic’s blockchain analytics platform is purpose-built to analyse on-chain data at this scale. “Tempo’s payment-specific blockchain infrastruct
RecVue Completes Acquisition of AiVidens18.3.2026 14:04:00 CET | Press release
Transaction advances RecVue RevOS into a unified revenue-to-cash Revenue Operating System RecVue, the leader in AI-powered billing and revenue management platforms for complex enterprise monetization, today announced it has completed the acquisition of AiVidens. By acquiring the cash management and collections platform, RecVue will enable enterprises to move beyond simple revenue automation to unify contract governance, billing, collections, revenue compliance, revenue sharing, and liquidity management all within a single revenue operating system. “This acquisition furthers our strategy to close the structural gap between revenue and cash,” said Nishant Nair, Founder and CEO of RecVue. “CFOs today are accountable not only for revenue accuracy, but for liquidity performance and working capital efficiency. With AiVidens, we are extending RevOS to connect commercial activity directly to cash realization.” While tasked with these widening responsibilities, enterprise CFOs struggle with dis
Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift18.3.2026 14:01:00 CET | Press release
Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity - from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign. The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut across the sector in 2024–2025, unprecedented policy uncertainty, accelerating AI adoption, and intensifying portfolio pressure, organizations must transform all functions simultaneously, not sequentially, to remain competitive. A Proven Leader Across Transactions and Transformations Stacey Petrey brings more than 25 years of experience and a track record spanning more than 75 completed transactions. Stacey served as a Partner in PwC’s Deals practice where she focused on integrations, separations, value creation, and change mana
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom